The takeaway
Pacira BioSciences, Inc. shows a pronounced seasonal pattern over 10 years of data — strongest in April (+5.7%) and softest in October (−5.4%).
Right now
In July, the stock has fallen 30% of years, averaging −3.5%, roughly 5.7 pts behind the S&P 500.
The full picture
Pacira BioSciences, Inc.'s most dependable month has been April, higher in 6 of 10 years; October has been its least reliable, up just 30% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 | ||||||||||||
| 2017 | ||||||||||||
| 2016 |
Month by month
The stock's clearest edge over the S&P 500 lands in April (+4.0 pts); it has trailed the market most in October (−6.4 pts).
“vs S&P” is Pacira BioSciences, Inc.’s average for a month minus the S&P 500’s average for that same month — isolating Pacira BioSciences, Inc.’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, April has closed higher 40% of the time versus 60% across the last 10 years — the pattern is weakening.
Figures are the typical (median) April return and how often it rose — the last 5 years versus the last 10(the heatmap’s default window). This verdict stays anchored to that 10-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
The year leans April's way without overwhelming the rest of it: the stock has closed higher in 6 of 10 Aprils, its most dependable month if not a dominant one.
Its average (+5.7%) and median (+5.7%) land within a hair of each other — the tell of steady, year-after-year gains rather than one outlier doing the work. That reliability comes with real swings, mind — even April ranges by 11.8% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: April has cleared the S&P 500 by +4.0 points above the index.
A few other months pull their weight: January and December have also closed higher more often than not. On the other side of the ledger, October has been the soft spot — the weakest of 7 months that average a loss (−5.4%), and the edge isn't year-round — the stock has trailed the S&P 500 in October, July, and May. Its roughest month on record was a −28.7% June in 2016 — a reminder of how hard even a seasonal name can fall.
The pattern has softened of late, April's last five years slipping below its longer-run record.
Treat it as a tendency rather than a rule — seasonality describes the past, not a promise.
Short answers on the stock's best month (April), its worst (October), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2016 its best month (April, +5.7%) has run well ahead of its worst (October, −5.4%) — the heatmap above shows how steady that gap has been year to year.
April has been the strongest, averaging +5.7% and closing higher in 6 of 10 years since 2016.
It's the weakest, averaging −5.4% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade